IFNA1 and chronic hepatitis C virus infection: The objectives of this study were to assess the efficacy and safety of CIFN and RBV in patients with chronic hepatitis C genotype 3 who were non-responders or relapsers to previous therapy with Peg-IFNα 2a or 2b and RBV.